Related by context. All words. (Click for frequent words.) 69 GALNS 68 Bronchitol 68 LymphoStat B 67 Phase 2a 66 elagolix 66 Phenoptin 65 Phase 2b study 65 Phase 1b 65 PROMACTA 65 elotuzumab 65 motavizumab 65 Plicera 65 otelixizumab 64 Denufosol 64 PXD# 64 bosentan 64 Phase 2a trial 64 Phase IIb clinical 64 Amigal 64 phase IIb clinical 64 forodesine 64 Zerenex 64 phase IIb 64 Traficet EN 64 phase 2a 63 ISIS # 63 Dacogen injection 63 phase IIa clinical 63 CIMZIA TM 63 eltrombopag 63 riociguat 63 Phase IIa clinical 63 axitinib 63 pharmacokinetic PK 63 Phase 2a clinical 63 dirucotide 63 placebo controlled clinical 63 velafermin 63 NGX# 63 valopicitabine 62 talactoferrin 62 ATACAND 62 adalimumab 62 oral ridaforolimus 62 HuMax CD4 62 TACI Ig 62 apremilast 62 Phase IIb trial 62 amrubicin 62 ambrisentan 62 Fibrillex TM 62 INCB# [001] 62 Phase Ib 62 phase IIa 62 lintuzumab 62 RSD# oral 62 daclizumab 62 CR# vcMMAE 62 MAP# 62 Phase Ib clinical 62 lomitapide 62 ruboxistaurin 62 Phase 1b trial 62 glufosfamide 62 registrational 61 albinterferon alfa 2b 61 alvespimycin 61 fostamatinib 61 Ventavis 61 GAMMAGARD 61 EVIZON 61 ARIKACE 61 canakinumab 61 arzoxifene 61 Relovair 61 ILLUMINATE 61 TBC# 61 HuMax CD# 61 varespladib 61 ganetespib 61 Phase IIa trial 61 bicifadine 61 Phase 2b trial 61 vidofludimus 61 confirmatory Phase III 61 CIMZIA ™ 61 XmAb# 61 methylnaltrexone 61 Phase IIB 61 Nasulin 61 teduglutide 61 phase IIb trial 61 registrational trial 61 Genz # 61 oral prodrug 61 ocrelizumab 61 ruxolitinib 61 certolizumab pegol 61 Bicifadine 61 Catena ® 61 UPLYSO 61 INCB# [002] 61 Phase 2b 61 aclidinium bromide 61 Phase Ib study 61 Marqibo 61 Phase IIa 61 Numax 61 Phase IIb 61 GSK# [001] 61 PEG PAL 60 Phase IIb trials 60 ALN RSV# 60 pegloticase 60 placebo controlled Phase 60 HCD# [002] 60 Phase #/#a 60 FOLOTYN 60 ataluren 60 zileuton 60 pralatrexate 60 aleglitazar 60 vandetanib 60 Targretin 60 PRT# 60 multicenter Phase 60 unblinding 60 HCV RESPOND 2 60 PREZISTA r 60 Nuvion 60 TOLAMBA 60 RRMS patients 60 obatoclax 60 Phase #b/#a trial 60 phase IIb study 60 ProSavin 60 nalbuphine ER 60 HuMax EGFr 60 ELND# 60 BRIM2 60 BAY #-# 60 blinatumomab 60 liprotamase 60 Clolar 60 enzastaurin 60 dose escalation Phase 60 FTY# 60 ACTEMRA TM 60 AZILECT R 60 OMAPRO 60 ozarelix 60 dose cohort 60 Ceflatonin 60 Phase IIIb clinical 60 tanespimycin 60 pomalidomide 60 SYMBICORT 60 PEG Interferon lambda 60 AZILECT ® 60 Zelrix 60 randomized Phase IIb 60 atacicept 60 PRX # 60 Phase 2b clinical 60 IDX# 59 NATRECOR R 59 Triolex 59 bronchodilation 59 bardoxolone 59 NUVIGIL 59 Bezielle 59 GATTEX 59 PREOS 59 MYDICAR ® 59 rALLy 59 Alzhemed TM 59 placebo controlled trials 59 metastatic RCC 59 incyclinide 59 Phase IIa trials 59 Phase 1a 59 QNEXA 59 Kuvan 59 phase Ib 59 SILENOR TM 59 sunitinib 59 sitaxsentan 59 tgAAC# 59 non metastatic osteosarcoma 59 Tarceva TM 59 MERLIN TIMI 59 BRIM3 59 NEVO ™ 59 tiotropium 59 randomized Phase III 59 Surfaxin LS 59 PS# [001] 59 QLT# 59 talabostat 59 diabetic neuropathic pain 59 Troxatyl 59 alvimopan 59 Viramidine 59 pradefovir 59 cariprazine 59 Arikace 59 maribavir 59 dosing cohort 59 SinuNase 59 active comparator 59 subcutaneously administered 59 dacetuzumab 59 Cimzia TM 59 Neurodex 59 ELACYT 59 VPRIV 59 Trizytek 59 placebo controlled clinical trials 59 Vernakalant 59 abatacept 59 ORENCIA ® 59 HGS ETR1 59 brivaracetam 59 AEGR 59 DSMB recommended 59 Aurexis 59 microplasmin 59 Aclidinium 59 IMA# 59 ularitide 59 lupus nephritis 59 TOCOSOL Paclitaxel 59 AZD# 59 Vitaxin 59 EOquin 59 abiraterone acetate 59 FROVA 59 L MTP PE 59 Onrigin 59 nab paclitaxel 59 refractory angina 59 clinical pharmacology studies 59 iSONEP 59 denufosol tetrasodium 59 Golimumab 59 CoFactor 59 Pirfenidone 59 ASA# 59 R#/MEM # 59 BLA submission 59 Cethromycin 59 aerosolized KL4 surfactant 59 iclaprim 59 TroVax ® 58 ACZ# 58 torezolid phosphate 58 Azedra 58 YERVOY 58 ponatinib 58 safinamide 58 prGCD 58 Archexin 58 lucinactant 58 darapladib 58 cangrelor 58 efalizumab 58 ALKS 58 celgosivir 58 davunetide 58 PSN# [002] 58 Virulizin ® 58 LAF# 58 confirmatory clinical 58 NLX P# 58 prospectively defined 58 ZALBIN dosed 58 etanercept 58 Aerosurf 58 nitazoxanide 58 teriflunomide 58 TELINTRA 58 velaglucerase alfa 58 regorafenib 58 castration resistant prostate cancer 58 dose escalation phase 58 TDF FTC 58 AIR CF1 58 laquinimod 58 glatiramer acetate 58 Quinamed 58 oritavancin 58 maximally tolerated dose 58 visilizumab 58 SUTENT 58 oral rivaroxaban 58 huC# DM4 58 ATL# [001] 58 PROSTVAC TM 58 confirmatory Phase 3 58 solifenacin 58 PEG SN# 58 oral FTY# 58 pazopanib 58 Probuphine 58 viral kinetic 58 IIa trial 58 bosutinib 58 sapacitabine 58 tivozanib 58 T Pred 58 Ophena TM 58 GOUT 58 Benlysta belimumab 58 efficacy endpoint 58 romiplostim 58 squalamine 58 omecamtiv mecarbil 58 custirsen 58 sunitinib malate 58 subcutaneous PRO 58 ADHF 58 EOquin TM 58 HspE7 58 MAXY alpha 58 oral methylnaltrexone 58 TORISEL 58 ascending dose 58 ALTU 58 HZT 58 ACTEMRA 58 Clolar ® 58 Albuferon 58 eosinophilic asthma 58 refractory gout 58 enoximone 58 cetrorelix 58 Sandostatin LAR 58 tasocitinib 58 metastatic HRPC 58 secondary efficacy endpoints 58 indacaterol 58 ZYBRESTAT 58 PRECISE Trial 58 JAK inhibitor 58 ciclesonide 58 APTIVUS r 58 NEBIDO 58 Omigard 58 AeroLEF TM 58 tramiprosate Alzhemed TM 58 BLA filing 58 NP2 Enkephalin 58 Vilazodone 58 Phase 1b clinical 58 NVA# 58 cannabinor 58 ONGLYZA 58 bevirimat 58 tramiprosate 58 CUSTOM III 58 Restanza 58 pharmacokinetic studies 58 Zenvia ™ 58 Unit Dose Budesonide 58 GLP toxicology studies 58 treatment naive genotype 58 panitumumab 58 vemurafenib 58 investigational monoclonal antibody 58 mCRC patients 58 Gattex 58 Phase 1a clinical 58 decitabine 58 rALLy trial 58 XGEVA 58 6R BH4 58 interferon beta 1b 58 pivotal Phase III 58 RSV infection 57 INT# [002] 57 ALVESCO HFA 57 OncoVEX GM CSF 57 orBec 57 multicenter Phase II 57 hour bronchodilation 57 Laquinimod 57 Capesaris 57 vicriviroc 57 Octreolin 57 SRT# [003] 57 rindopepimut 57 ZACTIMA 57 R# #mg BID 57 pirfenidone 57 Torisel 57 Corlux 57 Pralatrexate 57 PRISTIQ 57 Allovectin 7 R 57 Relivar 57 Pixuvri 57 MYDICAR 57 DAPT 57 refractory CLL 57 dimebon 57 HoFH 57 Mylotarg 57 Menveo 57 XL# SAR# 57 neurogenic orthostatic hypotension 57 MBP# [001] 57 dalbavancin 57 exenatide LAR 57 Icatibant 57 Onbrez Breezhaler 57 TRIOLEX 57 CRLX# 57 Mipomersen 57 pharmacokinetic PK study 57 mRCC 57 Acetavance 57 Cimzia ® 57 HCV SPRINT 57 midstage trials 57 pegaptanib 57 elacytarabine 57 CIMZIA TM certolizumab pegol 57 aflibercept 57 colesevelam HCl 57 omega interferon 57 treprostinil 57 bendamustine 57 AVADO 57 REMINYL ® 57 tramiprosate ALZHEMED TM 57 balsalazide tablet 57 iloperidone 57 Stedivaze 57 SAR# [004] 57 LymphoStat B belimumab 57 BENLYSTA ® 57 Cinryze 57 multicenter clinical 57 Dextofisopam 57 LY# [003] 57 Anthim 57 Promacta 57 Denosumab 57 Phase 2b clinical trials 57 tasimelteon 57 PF # [001] 57 RSD# 57 clinical trial 57 AGILECT R 57 rilonacept 57 Phase III clinical 57 MAA submission 57 IMC A# 57 rolofylline 57 TELCYTA 57 peginterferon alfa 2a 57 tezampanel 57 investigational compound 57 DXL# 57 ONTAK 57 LibiGel 57 ranibizumab 57 IMPACT DCM clinical 57 pharmacodynamic profile 57 ofatumumab 57 AFREZZA 57 OncoGel 57 paliperidone ER 57 HGS ETR2 57 MyVax R 57 ONGLYZA ™ 57 ZOLINZA 57 receptor tyrosine kinase inhibitor 57 Pivotal Phase 57 CTAP# Capsules 57 insulin degludec 57 ZD# [001] 57 eculizumab therapy 57 SinuNase TM 57 PRTX 57 Raptiva ® 57 TREANDA 57 MAGE A3 ASCI 57 ARCOXIA 57 metastatic renal cell carcinoma 57 neratinib 57 DR Cysteamine 57 Phase III 57 urocortin 2 57 Sym# 57 Iluvien 57 Cinryze TM 57 OXi# 57 PRIMO CABG 57 JANUVIA 57 pharmacodynamic PD 57 compound INCB# 57 OHR/AVR# 57 Valortim 57 OvaRex ® MAb 57 APPRAISE 57 tolvaptan 57 desvenlafaxine succinate 57 MLN# 57 motesanib 57 Phase #b/#a 57 rasagiline 57 tremelimumab 57 ThGRF 57 recurrent glioma 57 pharmacokinetics PK 57 Prolacria 57 EXJADE 57 picoplatin 57 galiximab 57 BCX# 57 STRIDE PD 57 LCP Tacro 57 SVR# 57 isavuconazole 57 biologic therapy 57 FACTIVE tablets 57 mcg dose 57 FOLOTYN ® 57 JAK inhibitors 57 Technosphere Insulin 57 RG# [001] 57 lixisenatide 57 KAPVAY ™ 57 terlipressin 57 rFIXFc 57 Tavocept 57 Phase III HEAT 57 CANCIDAS 57 Ozarelix 56 TPI ASM8 56 Fx #A 56 Kamada AAT 56 Syncria 56 RIGScan CR 56 senicapoc 56 DU #b 56 aldosterone antagonists 56 dexanabinol 56 Firazyr 56 plus dexamethasone 56 inhaled liposomal ciprofloxacin 56 chronic HCV infection 56 mipomersen 56 Dapagliflozin 56 ancrod 56 Betaferon ® 56 azacitidine 56 Empatic 56 Synavive 56 TYGACIL 56 lacosamide 56 sustained virologic response 56 metastatic hormone refractory 56 dasatinib 56 unblinded 56 edoxaban 56 Aflibercept 56 dexpramipexole 56 Telintra 56 Hepsera 56 trastuzumab DM1 T DM1 56 Lu AA# 56 cethromycin 56 APOPTONE 56 atrasentan 56 Emselex 56 Viprinex 56 CBLC# 56 olaparib 56 afatinib 56 SNT-MC#/idebenone 56 randomized Phase 2b 56 Cethrin 56 efficacy tolerability 56 bifeprunox 56 #mg BID [001] 56 Proxinium TM 56 ISENTRESS 56 Board DSMB 56 Ostarine 56 deforolimus 56 multicenter placebo controlled 56 Behcet uveitis 56 posaconazole 56 Exelixis compounds 56 PROSTVAC ® 56 vernakalant 56 etravirine 56 placebo controlled Phase III 56 APTIVUS 56 pseudobulbar affect PBA 56 gemifloxacin 56 EndoTAG TM -1 56 severe gastroparesis 56 GLYX 56 Phase IIIb 56 CRx 56 favorable pharmacokinetic profile 56 cediranib 56 docetaxel chemotherapy 56 viral kinetics 56 Pivotal Trial 56 imatinib therapy 56 placebo controlled studies 56 Inhaled nitric oxide 56 administered subcutaneously 56 EFAPROXYN 56 Menerba 56 Increlex ® 56 budesonide foam 56 baminercept 56 ATL/TV# 56 XL# [003] 56 tipifarnib 56 initiate Phase 1b 56 diabetic macular edema 56 vosaroxin 56 VEGF Trap 56 Urocortin 2 56 BioSTAR R 56 CA4P 56 generation purine nucleoside 56 Dasatinib 56 Amrubicin 56 naronapride 56 dose escalation clinical 56 Aryplase 56 Vandetanib 56 Diabetic Macular Edema 56 HQK 56 cilengitide 56 Phase IIb clinical trials 56 ezogabine 56 Evoltra ® 56 TMC# [001] 56 Civacir 56 TroVax 56 Jevtana 56 Reverset 56 BENLYSTA 56 darusentan 56 QVA# 56 interferon gamma 1b 56 mapatumumab 56 ToGA 56 recurrent malignant glioma 56 tafamidis 56 cystinosis patients 56 certolizumab 56 HCV infected 56 BEXXAR 56 palonosetron 56 idiopathic pulmonary fibrosis IPF 56 PegIFN RBV 56 PDE4 inhibitor 56 clazosentan 56 alteplase 56 ongoing Phase 1b 56 Folotyn 56 tesmilifene 56 GVAX 56 eniluracil 56 SCH # 56 HuLuc# 56 CCX# 56 recurrent glioblastoma 56 Pimavanserin 56 ipilimumab 56 seropositive patients 56 Fodosine 56 Phase III clinical trials 56 ulimorelin 56 TASKi2 56 muraglitazar 56 Cimzia R 56 Allovectin 7 ® 56 antibody MAb 56 aclidinium 56 figitumumab 56 Ceplene 56 NATRECOR ® 56 Sprycel dasatinib 56 low dose cytarabine 56 multiple ascending dose 56 RGB # 56 prucalopride 56 myelodysplastic syndromes MDS 56 thorough QT 56 HGS# 56 atherothrombotic events 56 IRX 2 56 RezularTM 56 YONDELIS 56 L PPDS 56 rFVIIa 56 peginterferon 56 nonrandomized 56 TMC# [002] 56 RLY# 56 INC# 56 pertuzumab 56 clinical trials 56 bapineuzumab 56 perifosine 56 trospium 56 antiepileptic drug 56 ORENCIA R 56 GRN# 56 gefitinib Iressa 56 mg kg dose 56 pharmacokinetic PK profile 56 virus HCV protease inhibitor 56 Tanespimycin 56 tocilizumab 56 salmeterol fluticasone 56 Lung transplantation 56 Phenserine 56 lubiprostone 56 Vectibix monotherapy 56 PA# [002] 56 alemtuzumab Campath 56 Phase III psoriasis 56 QAB# 56 telaprevir 56 Evoltra 56 EGFR TKI 56 RhuDex 56 anticancer compound 56 Xyotax 56 ABSORB trial 56 CYPHER R Sirolimus eluting 56 SPIRIVA HandiHaler 56 AZOR 56 Annamycin 56 Diamyd ® 56 SNT MC# 56 AERx iDMS 56 investigational humanized monoclonal antibody 56 eprotirome 56 OMNARIS Nasal Spray 56 MACUGEN 56 mGluR5 NAM 56 Altastaph 56 zileuton CR 56 divalproex sodium 56 AIR CF2 56 DCCR 56 randomized controlled Phase 56 SYMMETRY trial 55 synthetic retinoid 55 dose dose escalation 55 leukemia AML 55 tezampanel NGX# 55 angiogenesis inhibitor 55 ximelagatran 55 Phase III confirmatory 55 davunetide intranasal AL 55 C1 INH 55 ENRICH trial 55 LEXIVA r 55 Peg IFN 55 RSR# 55 Nanobody 55 AzaSite Plus 55 Serada 55 CDP# 55 octreotide implant 55 Desmoteplase 55 Ocrelizumab 55 Zenvia 55 Luveniq 55 pharmacodynamic 55 Leukine 55 alagebrium 55 post menopausal osteoporosis 55 pivotal Phase 55 Prestara 55 omacetaxine mepesuccinate 55 Kynapid 55 relapsed multiple myeloma 55 Initiated Phase 55 Abatacept 55 lumiliximab 55 IRESSA 55 Cotara 55 PRECiSE 55 SPIRIT FIRST 55 heavily pretreated 55 dirucotide MBP# 55 tarenflurbil 55 telcagepant 55 rALLy clinical trial 55 Naglazyme 55 reslizumab 55 Azilect ® 55 AA Amyloidosis 55 cetuximab Erbitux 55 antiretroviral naive 55 CytoFab 55 Pivotal Phase III 55 TNF inhibitor 55 ROTATEQ 55 eprodisate Fibrillex TM 55 SparVax TM 55 COU AA 55 linaclotide 55 belimumab 55 subgroup analyzes 55 roflumilast 55 tecarfarin 55 temsirolimus 55 Pafuramidine 55 Tasimelteon 55 TYKERB 55 GLP1 agonist 55 Levadex 55 eculizumab 55 Phase #/#a trial 55 Azixa 55 Dendreon Provenge 55 Entereg R 55 Entereg 55 rHuPH# 55 sipuleucel T 55 recurrent GBM 55 vilazodone 55 edifoligide 55 CINTREDEKIN BESUDOTOX 55 CYCLOSET 55 belinostat 55 danoprevir 55 MAXY G# 55 Pegasys plus Copegus 55 infliximab 55 Androxal 55 Serdaxin 55 Fampridine SR 55 Zalbin 55 AIM HIGH 55 L BLP# 55 AP# [003] 55 PRIMO CABG2 55 achieved statistical significance 55 ZFP Therapeutic 55 TNF antagonist 55 Fludara 55 NDA submission 55 telbivudine 55 systemically administered 55 MADIT II 55 evaluating Actimmune 55 StaphVAX 55 dabigatran etexilate 55 goserelin 55 ADAGIO study 55 GFT# 55 SPRYCEL 55 odanacatib 55 pharmacodynamic properties 55 dose cohorts 55 ostarine 55 ribavirin RBV 55 Q#IR 55 rhThrombin 55 BYDUREON 55 placebo controlled dose escalation 55 OncoVEX 55 relapsed refractory multiple myeloma 55 assessing T DM1 55 MyVax 55 tolerability 55 imetelstat 55 cMET 55 ORMD 55 mg BID 55 Aplidin 55 randomized multicenter 55 LymphoStat B TM 55 ABC/3TC 55 PROPEL trial 55 CYT# 55 ONCONASE R 55 metastatic malignant melanoma 55 Atrasentan 55 Dose escalation 55 liposomal ciprofloxacin 55 Stimuvax 55 rapid virologic response 55 TMC# C# 55 refractory chronic lymphocytic 55 dose escalation study 55 fosbretabulin 55 NOXAFIL 55 CTA# Injection 55 chlorambucil 55 relapsed SCLC 55 zalutumumab 55 APRISO 55 LUX Lung 55 almorexant 55 randomized multicenter Phase III 55 Allovectin 7 55 peginesatide 55 BIBW 55 dose titration 55 OPAXIO 55 Zenvia Phase III 55 LibiGel ® 55 ENESTnd 55 Alfimeprase 55 Randomized Phase 55 plus COPEGUS 55 Certolizumab pegol 55 APEX AMI trial 55 sargramostim 55 lesinurad 55 anti angiogenic therapy 55 Neupro R 55 omacetaxine 55 Asentar 55 FTY# fingolimod 55 plasma kallikrein 55 Keppra R 55 GSK# [002] 55 VA# [002] 55 VICTRELIS 55 HORIZONS AMI trial 55 TG# [003] 55 Aeroquin 55 anidulafungin 55 natalizumab 55 #D#C# 55 CERE 55 Phase Ib II 55 fenretinide 55 opioid induced bowel dysfunction 55 carfilzomib 55 dosing cohorts 55 Panzem R NCD 55 Augment Injectable 55 dose escalation 55 TYZEKA 55 palifosfamide 55 follicular NHL 55 doripenem 55 volociximab 55 Bortezomib 55 Sulonex 55 FIRMAGON R 55 EDEMA3 55 Miraxion 55 schizophrenia CIAS 55 ® natalizumab 55 selective modulator 55 Virulizin R 55 STELARA 55 Zemplar Capsules 55 TASKi3 55 AEG# 55 EVIZON TM squalamine lactate 55 Phase III trials 55 oxymorphone ER 55 IMC #B 55 Cinquil 55 EVEREST II 55 tolerability profile 55 #mg QD [001] 55 anti leukemic 55 RDEA# 55 #I TM# 55 calcineurin inhibitor 55 ADVANCE PD 55 USL# 55 Zentase 55 IND submission 55 noninfectious uveitis 55 TRO# 55 OMNARIS HFA 55 Safinamide 55 Gabapentin GR 55 Panzem 55 severe hypercholesterolemia 55 SomatoKine 55 PANVAC VF 55 KYNAPID 55 FOLFIRI 55 rotigotine 55 STX#